Business
Poxel Publishes Its Financial Results for the First Half of 2025
LYON, France, December 10, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the "Company"), announces today its condensed consolidated half-year financial results for the period ended June 30, 2025 and provides an update on recent events ahead of its
About this update from Poxel Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/b4cb5e0b86d5f22cae68836d02cacce8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MIF2Hjw4lFx5_PnOWKjCJw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b4cb5e0b86d5f22cae68836d02cacce8","width":480,"height":256}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue nearly doubled (+88%) and net loss reduced to €2.6 million in the first half of 2025","length":92,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Change in governance on August 1, 2025, following the filing of a declaration of insolvency and a request to open receivership proceedings with the Lyon Commercial Court (Tribunal des activités économiques)","length":206,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Commencement of receivership proceedings decided at the hearing on August 5, 2025, with a six-month observation period running until February 5, 2026","length":149,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Poxel's recovery plan, now finalized, is subject to the decision of the Lyon Commercial Court, which is expected early 2026","length":127,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The Statutory Auditors are expected to issue a disclaimer opinion (impossibilité de certifier) regarding Poxel's 2025 half-year condensed financial statements, given the pervasive uncertainty that could call into question the going concern assumption resulting from the aforementioned receivership proceedings – their report will be issued on Poxel's website at a later date","length":382,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"As a reminder, the shareholders’ general meeting will be held on December 11, 2025","length":82,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1038,"olType":false},{"type":"text","content":"LYON, France, December 10, 2025--(BUSINESS WIRE)--Regulatory News:","length":66,"tagName":"p"},{"type":"text","content":"POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic dise...